HSV thymidine kinase gene therapy

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHSV thymidine kinase gene therapy
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Herpes simplex virus vector
Mechanisms of ActionThymidine kinase stimulants
TargetsThymidine kinase
Therapy Area/IndicationsGraft vs Host DiseaseBrain NeoplasmsOvarian Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgEdison Biotechnology InstituteAvax Technologies Inc +[5] 
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversite Pierre Et Marie CurieNovartis Pharma AgAventis +[5] 
Active IndicationsN/A
Inactive IndicationsGraft vs Host DiseaseBrain NeoplasmsOvarian Neoplasms +[11] 

Other Information

ATC CodeN/A
Related LinksN/A